Friday, December 2, 2011

Hormonal prostate cancer therapy tied to blood clots

NEW YORK (Reuters Health) -

Hormone-targeted therapy for prostate cancer may raise the risk of potentially dangerous blood clots, a large U.S. study suggests.

Analyzing data on more than 154,000 older men with prostate cancer, researchers found that those who received hormonal therapy had double the rate of blood clots in the veins, arteries or lungs compared to men not on the treatment.

Of the 58,000-plus men taking hormonal therapy, 15 percent developed a blood clot over roughly four years, versus seven percent of men who did not receive get the therapy.

A clot in the blood vessels can prove fatal if it breaks loose and travels to the lungs, heart or brain.

For men weighing their options for prostate cancer treatment, Ehdaie said the risk of blood clots -- and other side effects -- needs to be balanced against the benefits.

Other potential side effects of hormonal therapy include weight gain, bone thinning, hot flashes and erectile dysfunction.

And for many prostate cancer patients, experts say, the benefits of hormonal therapy are not clear.


More Details Here:
Hormonal prostate cancer therapy tied to blood clots


Wednesday, November 16, 2011

Erectile Dysfunction Risk Grows with Number of Medications (LiveScience.com)

LiveScience.com -

Men who regularly take several medications are at increased risk for sexual problems , a new study says.

In the study, the more drugs men took, the higher their risk of erectile dysfunction (ED). Participants who took 10 or more medications were 1.6 times more likely to have ED compared with those who took fewer than two medications

The researchers aren't sure how the use of multiple medications may increase the risk of ED, but it's possible that interactions between medications may play a role.



Read the full report:
Erectile Dysfunction Risk Grows with Number of Medications

Thursday, November 3, 2011

Adding radiotherapy boosts prostate cancer survival

LONDON (Reuters) -

Adding radiotherapy to hormone drugs for prostate cancer patients significantly improves survival compared with hormone treatment alone, and the combination could save many lives if it were made standard practice, scientists said Thursday.

In a study of men with prostate cancer -- the second most common form of cancer among men worldwide -- researchers found that 74 percent of those given radiotherapy plus hormone treatment were still alive after seven years.

This compared with 66 percent who got hormone drugs but did not receive radiotherapy, the researchers said

"The results of this trial are extremely encouraging," said Matthew Sydes, senior scientist at Britain's Medical Research Council's Clinical Trials Unit, which helped conduct the study.

He said the additional side-effects of radiotherapy are "minimal," suggesting doctors could be confident in recommending the combination treatment for their patients.



Read the Full Article:
Adding radiotherapy boosts prostate cancer survival


Wednesday, October 26, 2011

Drinking More Fluids Could Lower Men's Bladder Cancer Risk (HealthDay)

TUESDAY, Oct. 25 (HealthDay News) --

Men who drink plenty of low-sugar fluids may reduce their risk for bladder cancer, new research suggests.

Although the reason for the association between fluid intake and protection against cancer remains unknown, researchers theorize the fluids may flush out potential cancer-causing agents before they have a chance to cause any damage.

The investigators found that the men with a high daily fluid intake, or those who drank more than 10 cups (2,531 milliliters) per day, had a 24 percent reduced risk for bladder cancer. The study authors concluded that doctors should tell their patients to drink plenty of low-sugar fluids.

This research should be viewed as preliminary until published in a peer-reviewed journal.

Read More Here:
Drinking More Fluids Could Lower Men's Bladder Cancer Risk

Thursday, October 20, 2011

Medtronic tests stent for erectile dysfunction

(Reuters) -

Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.

The medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED), each of whom had a stent -- a tiny wire mesh tube similar to those used to prop open heart arteries -- which was placed in the internal pudendal artery, which supplies blood to the penis.. After three months the results were promising, the company said.

Researcher Dr. Jason Rogers said up to 50 percent of men discontinue drug therapy -- which includes Viagra, Levitra and Cialis -- either because it did not work or because they could not tolerate side effects, including lowering of blood pressure.

Rogers noted that there were no adverse events reported by participants in the trial up to three months later, but heacknowledged that risks may become evident much later and stressed that the stenting procedure is still investigational and requires more research.


Read More:

Medtronic tests stent for erectile dysfunction



Wednesday, October 19, 2011

Male breast cancer rare, but can be aggressive

NEW YORK (Reuters Health) -

Men get diagnosed with breast cancer at less than one percent the rate of women, according to a new analysis of cancer rates from six cities and countries.

But when they did get breast cancer, men were caught with more advanced disease, on average, and were more likely to die from it.

Men are most commonly in their 60s or 70s when diagnosed with breast cancer, according to the National Cancer Institute. Radiation exposure and diseases that increase estrogen levels - such as liver cirrhosis or Klinefelter syndrome, a genetic disorder - are among factors that raise a man's risk.

The United States Preventive Services Task Force, a federally-supported panel that sets guidelines for cancer screening, does not recommend regular breast cancer screening in men without symptoms.

Read the full report:
Male breast cancer rare, but can be aggressive


Friday, October 14, 2011

Infections after prostate biopsy on the rise

NEW YORK (Reuters Health) -

Serious infections after prostate biopsies appear to be on the rise in the U.S., possibly fueled by antibiotic-resistant bacteria, a new study of elderly men suggests.

More than a million prostate biopsies are done each year on Medicare patients, often to investigate suspicious results from prostate cancer screening. But the majority of those are false alarms, and some doctors worry that many men could be suffering needlessly due to screening.

Just last week, a government-funded expert panel concluded that prostate cancer screening saves few or no lives, but causes harm through treatment or further invasive testing such as biopsies.

Read more:
Infections after prostate biopsy on the rise